垂体腺瘤个体中生殖系致病性CHEK2变异患病率增加
该研究评估了165例垂体腺瘤患者中CHEK2变异的频率和致病性,在5例(3.0%)患者中检出罕见编码非 synonymous 生殖系CHEK2变异,其中2个为明确无效变异(致病性),2个为错义变异(可能致病性),仅考虑无效变异时频率仍高于国家对照数据(1.8% vs 0.5%;P = .049)。结论首次提示CHEK2在垂体肿瘤发生中可能起作用。
要点
- 165例垂体腺瘤患者中5例(3.0%)携带罕见编码非 synonymous 生殖系CHEK2变异,未发现体细胞变异。
- 检出的变异包括2个致病性无效变异和2个可能致病性错义变异,患者涵盖多种垂体腺瘤类型。
- 仅计无效变异时,队列中CHEK2变异频率仍高于国家对照数据(1.8% vs 0.5%;P = .049)。
核心结论
- 首次提示乳腺癌易感基因CHEK2可能在垂体肿瘤发生中起作用,3%的垂体腺瘤患者携带致病/可能致病性变异。
- 垂体腺瘤相对常见且通常缺乏典型常染色体显性家族史,此类风险等位基因可能是一般人群中垂体腺瘤风险的重要贡献因素。
研究设计与样本
- 研究评估了165例垂体腺瘤患者的CHEK2变异,包括一个29例接受生殖系和肿瘤全外显子组测序的原发队列,以及一个136例的独立队列(52例对生殖系和肿瘤DNA进行靶向下一代测序,84例仅对生殖系DNA测序)。
主要发现
- 原发队列29例中3例(10.3%)检出罕见编码非 synonymous 生殖系CHEK2变异,总体165例中5例(3.0%)检出,受累患者具有多种垂体腺瘤类型(泌乳素瘤、促甲状腺素瘤、生长激素瘤和无功能垂体腺瘤)。
- 未发现体细胞变异。
- 2个变异为明确无效变异(c.1100delC、c.444 + 1G > A),分类为致病性;2个变异为错义变异(p.Asn186His、p.Thr476Met),分类为可能致病性。
- 仅考虑无效变异时,队列中CHEK2变异频率仍高于国家对照数据(1.8% vs 0.5%;P = .049)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: CHEK2 is a cell cycle checkpoint regulator gene with a long-established role as a clinically relevant, moderate risk breast cancer predisposition gene, with greater risk ascribed to truncating variants than missense variants. OBJECTIVE: To assess the rate and pathogenicity of CHEK2 variants amongst individuals with pituitary adenomas (PAs). METHODS: We assessed 165 individuals with PAs for CHEK2 variants. The study population comprised a primary cohort of 29 individuals who underwent germline and tumor whole-exome sequencing, and a second, independent cohort of 136 individuals who had a targeted next-generation sequencing panel performed on both germline and tumor DNA (n = 52) or germline DNA alone (n = 84). RESULTS: We identified rare, coding, nonsynonymous germline CHEK2 variants amongst 3 of 29 (10.3%) patients in our primary cohort, and in 5 of 165 (3.0%) patients overall, with affected patients having a range of PA types (prolactinoma, thyrotropinoma, somatotropinoma, and nonfunctioning PA). No somatic variants were identified. Two variants were definitive null variants (c.1100delC, c.444 + 1G > A), classified as pathogenic. Two variants were missense variants (p.Asn186His, p.Thr476Met), classified as likely pathogenic. Even when considering the null variants only, the rate of CHEK2 variants was higher in our cohort compared to national control data (1.8% vs 0.5%; P = .049). CONCLUSION: This is the first study to suggest a role for the breast cancer predisposition gene, CHEK2, in pituitary tumorigenesis, with pathogenic/likely pathogenic variants found in 3% of patients with PAs. As PAs are relatively common and typically lack classic autosomal dominant family histories, risk alleles-such as these variants found in CHEK2-might be a significant contributor to PA risk in the general population.
引用
- De Sousa SMC, McCormack A, Orsmond A, et al. Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas. J Clin Endocrinol Metab. 2024. PMID: 38651569. doi:10.1210/clinem/dgae268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。